ArticleThe Lancet regional health. Western Pacific2022

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.

Ai-Min Hui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.